Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more) AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

Healthcare Industrials Auto Parts Drug Manufacturers - Specialty & Generic Diversified Industrials
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda’s Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.


TSX:HLS - Post by User

HLS Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • ImlearningX
Comment by Imlearningon Jun 12, 2023 12:23pm
205 Views
Post# 35491689

RE:not just one but two cantechletter.com articles

RE:not just one but two cantechletter.com articlesThanks for posting this.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities